The single-shot drug Nirsevimab, which can prevent the Respiratory Syncytial Virus (RSV) in infants, is short in supply. The Children’s Hospital Association says this will limit its impact this respiratory disease season. This drug, marketed as Beyfortus, cuts the risk of RSV-related hospitalization in infants by about 80% and, though supply constraints mean vulnerable infants are the priority, demand exceeds supply. The manufacturer AstraZeneca apparently underestimated the demand for the drug, despite its potential to prevent RSV.
Hackers Exploiting React Server Components Vulnerability in the Wild to Deploy Malicious Payloads
Two months following the disclosure of CVE-2025-55182, exploitation activity targeting React Server Components has evolved from broad scanning into consolidated, high-volume attack campaigns. According to
